Welcome to BioSeeker Group!

Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors

Additional Information

Published Date Aug 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5842
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the mechanism/target/effect of Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer
The breast cancer drug report part comprises defined and up to date development strategies for 470 drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Breast Cancer
5.1 The Scope of this Report 32
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (234 Drug Targets) 36-522
7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development (223 Drug Target Strategies and 470 Drugs) 523-797
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Compound Strategies) 798-850
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator (247 Investigators and 470 Drugs) 851-1723
10 Disclaimer 1724
Figures: Includes 8 Figures
Tables: Includes 309 Tables
Total Number of Pages: 1,755

Part II: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
A&G Pharmaceutical
AB Science
Abbott
Abiogen
Acceleron Pharma
Access
ACT Biotech
Actinium Pharmaceuticals
Adherex
Advanomics
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Allist Pharmaceuticals
Allos Therapeutics
Allostera
Alnis Biosciences
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Amgen
Amphora
AngioChem
Ansaris
Antisoma
Aphios
Apogee Biotechnology
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascend Therapeutics
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
Beta Pharma
Betagenon
Bio-Path Holdings
BioAxone
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioMarin
Bionovo
BioSante
Biotecnol
Biotica Technology
Bioton
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Research Technology
Catalyst Biosciences
Cel-Sci
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CerRx
Chemokine Therapeutics
Chiesi
Chong Kun Dang
Choongwae
Chroma Therapeutics
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
CSL
Curacyte
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Domainex
Dong-A
Dongkook Pharm
Douglas
Dyax
ECI
Eisai
Elara Pharmaceuticals
Eleos
ElexoPharm
Eli Lilly
Emergent BioSolutions
Endoceutics
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
Eucodis
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Formula Pharmaceuticals
Fresenius
Galapagos
Galectin Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
GlyTag
Got-a-Gene
GPC Biotech
Gradalis
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
Heidelberg Pharma
Hoffmann-La Roche
Hospira
Hutchison China MediTech
Hypha Discovery
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incozen Therapeutics
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intarcia Therapeutics
Intas Biopharmaceuticals
Intellikine
Intezyne Technologies
Intradigm
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
KaloBios
Kalypsys
Kanisa
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Marina Biotech
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Memgen
Menarini
Merck & Co
Merck KGaA
Merrimack
MetaMol Theranostics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
Mologen
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NexGenix Pharmaceuticals
NexusPharma
NicOx
Nidus Laboratories
NIH
Nimbus Discovery
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
NovaLead
Novartis
Novogen
Oasmia
Oncalis
OncoGenex Pharmaceuticals
Oncolix
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Pacific Biotech
Paladin Labs
PanaGin
Pantarhei Bioscience
Pathway Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
PheneX
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
PIERIS Proteolab
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
ProStrakan
Provid
PTC Therapeutics
QLT
Quantum Pharmaceuticals
R&R
Radient Pharmaceuticals
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Samtheo Biopharma
Samyang
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
Savient Pharmaceuticals
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
SEEK
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
Sepal Pharma
Servier
SGX Pharmaceuticals
Shenogen
Shire
Sidus
Sigma-Tau
Silence Therapeutics
Sirnaomics
Southern Research Institute
Spirogen
SRI International
Stemline Therapeutics
Sun Pharma Advanced Research
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Taiho
Taiwan Liposome Company
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
Taxolog
TCD Pharma
TeGenero
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
to-BBB
ToolGen
TopoTarget
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trion Pharma
UCB
Vaccinex
Valeant
VasGene Therapeutics
Vaxon Biotech
Velacor Therapeutics
Verastem
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
ViroTarg
Wyeth
XBiotech
Xcovery
Xencor
Xerion
Xoma
Yakult Honsha
Yamasa Corporation
YM BioSciences
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
177-Lu-AMBA
17ß-hydroxysteroid dehydrogenase-1 inhibitors
2-methoxyestradiol
2aG4-IL-2 fus protein + PS MAb
4-hydroxytamoxifen
5-FU
852A
9-aminocamptothecin
AB-16B5
abiraterone acetate
ABT-510
AC-480
ACC inhibitor
acolbifene
adecatumumab
aderbasib
Adva-27a
AE-37
AEE-788
AEG-35156
AEZS-108
AF-802
afatinib
aflibercept
AFM-21
AG-1
agatolimod
aglycon protopanaxadiol
alemtuzumab
alvespimycin hydrochloride
alvocidib
amatuximab
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
amsacrine
amuvatinib
anastrozole
androgen receptor antagonist
angiopep+paclitaxel
Angiozyme
annamycin
anti-C35 MAb
anti-HER-2/neu antisense
anti-HER2 MAb
anti-HER2neu scFv
anti-Hsp90-alpha MAbs
anti-PCDGF MAbs
anticancers
antiestrogen
apatinib
apricoxib
AR-002
AR-004
AR-42
AR-7BD-33-11A
ARC-100
ARQ-197
ARQ-621
ARRY-380
arzoxifene hydrochloride
AS-1402
ASP-08126
AT-7519
AT-9283
atamestane
ATN-224
atrasentan
Auto TAG vaccine
AUY-922
AVE-1642
AVI-4126
avorelin
AVX-701
axitinib
AZD-1480
AZD-4547
AZD-4877
AZD-4992
AZD-8055
AZD-8931
bafetinib
BAL-27862
banoxantrone
barasertib
bardoxolone methyl
becatecarin
belinostat
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
bisantrene
BIW-8556
BMN-673
BMS-599626
BMS-690514
BMS-753493
BMS-754807
BMS-777607
BN-107
bortezomib
bosutinib
brca2
breast cancer therapy
breast cancer vaccine
BreMel/TNF-alpha
BrevaRex MAb
brivanib alaninate
brivudine
BZL-101
CAB-051
Cabozantinib
CAL-101
cancer therapy (1)
cancer therapy (2)
canertinib dihydrochloride
canfosfamide hydrochloride
capecitabine
carbetocin
catumaxomab
CBP-501
CC-223
CDX-1307
CEA cancer vaccine
cediranib
celecoxib
cetuximab
CGX-0682
CH-4986399
CHF-4227
cilengitide
cixutumumab
cladribine
clofarabine
CNF-2024
contusugene ladenovec
CP-724714
crizotinib
crolibulin
CSF-GM
CTCE-9908
CTP-37
CUDC-101
custirsen
CVac
CX-4945
CYN-101
cytarabine ocfosfate
cytarabine, injectable
D-3263
dabigatran etexilate
dacomitinib
dalotuzumab
danusertib
dasatinib
daunorubicin
decitabine
denosumab
Diflomotecan
dinaciclib
docetaxel (1)
docetaxel (2)
docetaxel (3)
docetaxel (4)
docetaxel (5)
docetaxel MAb
dovitinib lactate
doxifluridine
doxorubicin (1)
doxorubicin (10)
doxorubicin (11)
doxorubicin (2)
doxorubicin (3)
doxorubicin (4)
doxorubicin (5)
doxorubicin (6)
doxorubicin (7)
doxorubicin (8)
doxorubicin (9)
doxorubicin citrate
DXL-702
E-75
E39
ECI-301
elacytarabine
elomotecan
elsamitrucin
emepepimut-S
endostatin
endoxifen
eniluracil
ENMD-2076
enocitabine
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
epothilone D
erlotinib
ERR antagonists
ertumaxomab
estetrol
estrogen inhibitors
everolimus
exatecan mesylate
exemestane
Exherin
exisulind
EZH2
F16-IL2
fadrozole
FASN inhibitors
figitumumab
flt-4 kinase inhibitors
foretinib
formestane (1)
formestane (2)
fosfluridine tidoxil
fostamatinib disodium
FPI-01
fulvestrant
fusion toxins
Galactomycin-UCLT
galarubicin hydrochloride
ganitumab
gataparsen
GDC-0980
gefitinib
gemtuzumab ozogamicin
gimatecan
glembatumumab vedotin
GlyB4
golnerminogene pradenovec
goserelin
goserelin acetate ER
GPR40 antagonists
GSK-1059615
GSK-2118436
GSK-2130579A
GSK-2302024A
GVAX
HAS2 inhibitor
HE-3235
Her-2/Neu peptides
HER2 vaccine
her2/neu antigen
Her2/neu gene therapy
histamine dihydrochloride
huBrE-3 tiuxetan
HuMax-Her2
HuMax-VEGF
IC-83
icotinib hydrochloride
icrucumab
idarubicin
idronoxil
IGF-1 receptor inhibitor
IGN-101
IKKe/TBK1 inhibitor
imatinib mesilate
imetelstat
IMGN-388
immunogene therapy
IMO-2055
IMP-321
Imuteran
INCB-028060
indisulam
ING-1
ingenol mebutate
INGN-225
INGN-241
inherbins
iniparib
INNO-206
INSM-18
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon (ß1a)
interferon alpha-2b
interleukins
IPH-3102
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
irosustat
ispinesib mesylate
JI-101
JMR-132
KD032
KW-2170
KX2-391
labetuzumab
labetuzumab-SN-38
lapatinib ditosylate
lapuleucel-T
larotaxel
lasofoxifene
lenvatinib
leptin antagonists
lestaurtinib
letrozole
leucine-doxorubicin
leukemia vaccine
leuprorelin
linifanib
linsitinib
LipoVIL12
lonafarnib
lonaprisan
LOR-2040
Lovaxin B
lumiliximab
LY-2090314
LY-2157299
MAGH-22
masitinib
MDX-1140
ME-103
MEDI-547
Mesd-based peptides
MetXia
MGCD-265
MGN-1601
MGN-1703
midostaurin
milataxel
mitoxantrone
MK-1775
MK-2206
MKC-1
MLN-8237
MM-111
MM-121
MORAb-004
motesanib diphosphate
motexafin gadolinium
MP-529
MS-209
MT-110
MUC-1 vaccine
MVA-BN Her-2 vaccine
Nab-docetaxel
neratinib
nilotinib
nimotuzumab
NK-012
NL-0031
nolatrexed dihydrochloride
NPB-001-056
NXD-30001
OB-cadherin antibodies
obinutuzumab
oblimersen sodium
OCM-111
OCM-8054
OCM-8224
ofatumumab
OGX-225
OGX-427
olaparib
ON-01910
ON-045270
onartuzumab
Onco-L TCS
oncolytic viruses
OSI-027
OSI-7904L
osteolytic disease therapy
Osteopontin-c inhibitor


OTS-102
P276-00
paclitaxel (1)
paclitaxel (10)
paclitaxel (11)
paclitaxel (12)
paclitaxel (13)
paclitaxel (14)
paclitaxel (2)
paclitaxel (3)
paclitaxel (4)
paclitaxel (5)
paclitaxel (6)
paclitaxel (7)
paclitaxel (8)
paclitaxel (9)
paclitaxel polyglumex
paclitaxel-DHA
PankoPep
panobinostat
PANVAC-VF
patupilone
pazopanib hydrochloride
PD-0325901
PD-0332991
pegdinetanib
peginterferon alfa-2b
pelitinib
pemetrexed disodium
pentamidine isethionate
pentostatin
peptidomimetics
perifosine
pertuzumab
PHA-848125AC
PhG-alpha-1
pixantrone
PKI-179
PKI-587
plitidepsin
ponatinib
pralatrexate
Prolanta
Prolanta ER
prostate cancer therapy
PRX-321
PSK-3668
PTC-299
PX-104.1
PX-866
quinacrine
quizartinib dihydrochloride
R-763
radiotherapeutic
RAF-265
raloxifene hydrochloride
ramucirumab
razoxane
regorafenib
retaspimycin
Reximmune-C
Rexin-G
RG-1507
RG-7321
rhErbB3-f
rhIFN-alpha
ridaforolimus
rilotumumab
rinfabate
rituximab
romidepsin
RR-310
rubitecan
ruxolitinib
RX-0201-N
S1P3 inhibitor
sabarubicin
sagopilone
SAR-566658
saracatinib
SBC-202
Sch-57050
SCH-900776
SEL-24-1
seliciclib
selumetinib
semaxanib
seocalcitol
SERM + toxin
SF-1126
simotaxel
sipuleucel-T
siRNA gp96 therapy
sirolimus
SM3
SN-38 (1)
SN-38 (2)
SNG-163
SNG-8023
SNG-8038
sobuzoxane
sorafenib tosylate
SPC-2968
SR-13668
SR-16157
SR-31747
ß-lapachone
STA-9090
steroid sulfatase inhibitor
STP-503
SU-14813
SU-6668
sunitinib malate
survivin-2B
Symadex
talmapimod
talminogene laherparepvec
tamibarotene
tamoxifen (1)
tamoxifen (2)
tamoxifen, oral liquid
tandutinib
tanespimycin
tariquidar
TAS-108
tegafur + uracil
telatinib
telomerase vaccine
temsirolimus
Tenarad
teniposide
terameprocol
TG-4010
thiocoraline
thymectacin
tipifarnib
tivozanib
TLK-58130
TLN-4601
TNF + paclitaxel
TNF-alpha
toremifene citrate
trastuzumab (1)
trastuzumab (2)
trastuzumab (3)
trastuzumab emtansine
trastuzumab-MMAE conjugate
tremelimumab
triapine
triciribine phosphate
trilostane
triptorelin pamoate
TroVax
TS-1
TTL-2019
TTL-3101
UCN-01
V-930
V935
vandetanib
varlitinib
vatalanib
veliparib
vemurafenib
vismodegib
VM-206
volasertib
vosaroxin
VS-4718
VS-507
VS-5095
VX-001
WX-671
WX-UK1
XL-147
XL-281
XL-413
XL-647
XL-765
Y-90-labetuzumab
YM-155
Zemab
zibotentan
zorubicin
ZYC-300

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Learn More


Triple Analysis: Leukemia, Lung Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Adherens Junction Targeting in Oncology Drug Pipeline Update
BioSeeker Group have identified 277 companies plus partners who are today developing 357 targeting adherens junctions drugs in 1199 developmental projects in cancer across 134 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More


Triple Analysis: Melanoma, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More